2-(Ethyldisulfanyl)-2-methyl-butane

• 分子结构分类: 有机化合物 - 有机硫化合物 - 有机二硫化物
• 英文名称: 2-(Ethyldisulfanyl)-2-methyl-butane
• 英文别名: 2-(ethyldisulfanyl)-2-methylbutane
• 化学式: C₇H₁₆S₂
• 分子量: 164.3
• InChiKey: WWTMDKJIDVQUKF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  50.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION
  申请人：Manoharan Muthiah

  公开号：US20120035115A1

  公开（公告）日：2012-02-09

  The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.

  该发明涉及公式I或II的化合物：在一种实施方式中，该发明涉及化合物和用于将配体与寡核苷酸结合的过程。该发明进一步涉及治疗各种疾病和疾病的方法，例如病毒感染、细菌感染、寄生虫感染、癌症、过敏、自身免疫疾病、免疫缺陷和免疫抑制。
• COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE
  申请人：ALNYLAM PHARMACEUTICALS, INC.

  公开号：US20180135057A1

  公开（公告）日：2018-05-17

  The invention relates to antisense polynucleotide agents targeting the LECT2 gene, and methods of using such antisense polynucleotide agents to inhibit expression of LECT2 and to treat subjects having a LECT2-associated disease, e.g., amyloidosis.

  这项发明涉及针对LECT2基因的反义多核苷酸药剂，以及利用这种反义多核苷酸药剂抑制LECT2表达并治疗患有LECT2相关疾病（例如淀粉样变性）的受试者的方法。
• COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
  申请人：Alnylam Pharmaceuticals, Inc.

  公开号：US20150247143A1

  公开（公告）日：2015-09-03

  The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the complement component C5 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of C5 and to treat subjects having a complement component C5-associated disease, e.g., paroxysmal nocturnal hemoglobinuria.

  该发明涉及iRNA，例如双链核糖核酸（dsRNA），针对补体成分C5基因的组合物，以及使用这种iRNA，例如dsRNA，组合物来抑制C5的表达并治疗患有补体成分C5相关疾病的受试者，例如周期性夜间血红蛋白尿。
• Targeting Lipids
  申请人：Manoharan Muthiah

  公开号：US20090247608A1

  公开（公告）日：2009-10-01

  The present invention provides targeting lipids of structure L 100— linker—L 101 (CI), where L 100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L 101 is a ligand or —CH 2 CH 2 (OCH 2 CH 2 ) p O(CH 2 ) q CH 2 -ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

  本发明提供了结构为L100-连接物-L101(CI)的靶向脂质，其中L100是一种脂质、亲脂剂、烷基、烯基或炔基，L101是一种配体或-CH2CH2(OCH2CH2)pO(CH2)qCH2-配体，p为1-1000，q为1-20。此外，本发明还提供了用于向细胞传递治疗剂的组合物和方法。特别地，这些包括新型脂质和核酸-脂质颗粒，它们提供了核酸的高效封装和在体内高效传递封装的核酸到细胞的方法。
• Folate Conjugates
  申请人：Manoharan Muthiah

  公开号：US20090247614A1

  公开（公告）日：2009-10-01

  The present invention provides iRNA agent including at least one monomer having the structure shown in formula (I′) wherein: A and B are each independently for each occurrence O, N(R N ) or S; X is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a polymer, —P(Z′)(Z″)O-L 6 -Q′-L 7 -OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, or an oligonucleotide; Y is H, a protecting group, a phosphate group, a phosphodiester group, an activated phosphate group, an activated phosphite group, a phosphoramidite, a solid support, —P(Z′)(Z″)O-nucleoside, —P(Z′)(Z″)O-oligonucleotide, a lipid, a PEG, a steroid, a lipophile, a polymer, —P(Z′)(Z″)O-L 6 -Q′-L 7 -OP(Z′″)(Z″″)O-oligonucleotide, a nucleotide, or an oligonucleotide; R is folate, a folate analog a folate mimic or a folate receptor binding ligand; L 6 and L 1 are each independently for each occurrence —(CH 2 ) n —, —C(R′)(R″)(CH 2 ) n —, —(CH 2 ) n C(R′)(R″)—, —(CH 2 CH 2 O) m CH 2 CH 2 —, or —(CH 2 CH 2 O) m CH 2 CH 2 NH—; Q′ is NH, O, S, CH 2 , C(O)O, C(O)NH, —NH—CH(R a )—C(O)—, —C(O)—CH(R a )—NH—, CO, where R a is H or amino acid side; chain. R′ and R″ are each independently H, CH 3 , OH, SH, NH 2 , NH(Alkyl=Me, Et, Pr, isoPr, Bu, Bn) or N(diAlkyl=Me 2 , Et 2 , Bn 2 ); Z′, Z″, Z′″ and Z″″ are independently O or S; n represent independently for each occurrence 1-20; and m represent independently for each occurrence 0-50.

  本发明提供了iRNA试剂，包括至少一个单体，其结构如式（I'）所示，其中：A和B分别独立于每个出现的O、N（RN）或S；X是H、保护基、磷酸基、磷酸二酯基、活性磷酸基、活性磷酸酯基、磷酰胺基、固体支持、-P（Z'）（Z"）O-核苷、-P（Z'）（Z"）O-寡核苷酸、脂质、PEG、类固醇、聚合物、-P（Z'）（Z"）O-L6-Q' -L7-OP（Z' "）（Z" "）O-寡核苷酸、核苷酸或寡核苷酸；Y是H、保护基、磷酸基、磷酸二酯基、活性磷酸基、活性磷酸酯基、磷酰胺基、固体支持、-P（Z'）（Z"）O-核苷、-P（Z'）（Z"）O-寡核苷酸、脂质、PEG、类固醇、亲脂性物质、聚合物、-P（Z'）（Z"）O-L6-Q' -L7-OP（Z' "）（Z" "）O-寡核苷酸、核苷酸或寡核苷酸；R是叶酸、叶酸类似物、叶酸模拟物或叶酸受体结合配体；L6和L1分别独立于每个出现的-（CH2）n-、-C（R'）（R"）（CH2）n-、-（CH2）nC（R'）（R"）-、-（CH2CH2O）mCH2CH2-或-（CH2CH2O）mCH2CH2NH-；Q'是NH、O、S、CH2、C（O）O、C（O）NH、-NH-CH（Ra）-C（O）-、-C（O）-CH（Ra）-NH-、CO，其中Ra是H或氨基酸侧链；R'和R"各自独立于H、CH3、OH、SH、NH2、NH（Alkyl=Me、Et、Pr、isoPr、Bu、Bn）或N（diAlkyl=Me2、Et2、Bn2）；Z'、Z"、Z' "和Z" "各自独立于O或S；n独立于每个出现的1-20；m独立于每个出现的0-50。